[go: up one dir, main page]

BG107161A - 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors - Google Patents

5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Info

Publication number
BG107161A
BG107161A BG107161A BG10716102A BG107161A BG 107161 A BG107161 A BG 107161A BG 107161 A BG107161 A BG 107161A BG 10716102 A BG10716102 A BG 10716102A BG 107161 A BG107161 A BG 107161A
Authority
BG
Bulgaria
Prior art keywords
so2nr4r5
compounds
hydrogen
alkylpyrido
pyrimidines
Prior art date
Application number
BG107161A
Other languages
Bulgarian (bg)
Inventor
Richard Booth
Ellen Dobrusin
Peter Toogood
Scott VANDERWEL
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG107161A publication Critical patent/BG107161A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed are compounds of the formula wherein: R2 is hydrogen, alkyl, or cycloalkyl; R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro -COR4, -CO2R4, -CONR4R5, -CONR4OR5, -SO2NR4R5, -SO2NR4R5, -SO2R4, -SO3R4, formula (II) given in the description, or -NR4R5; Y is N or CR7, wherein R7 and Z can be R9 is lower alkyl, haloalkyl, or aryl, X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(O)R4R5, -NR4r5R6W, -SR4, -C(O)R4, -CO2R4, -CONR4R5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), -T(CH2)mQR4, -C(O)T(CH2)mQR4, or -NR4C(O)T(CH2)mQR5; m is 1 to 6. These compounds are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of cyclin-dependant kinases (cdks) and growth factor-mediated kinases. 23 claims
BG107161A 2000-03-06 2002-10-02 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors BG107161A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BG107161A true BG107161A (en) 2003-06-30

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107161A BG107161A (en) 2000-03-06 2002-10-02 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN1847229B (en) 2000-10-23 2011-05-04 史密丝克莱恩比彻姆公司 2,4,8- trisubstituted-8H- pyridine[2,3-d] pyridine -7-one compound
CN100376571C (en) * 2001-02-12 2008-03-26 霍夫曼-拉罗奇有限公司 6-substituted pyridopyrimidines
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co PYRIDOPYRIMIDINE OR NAPHTHYRIDINE DERIVATIVE
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
ES2251677T3 (en) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2- (PIRIDIN-2-ILAMINO) -PIRIDO (2,3-D) PIRIMIDIN-7-ONAS.
EP1499320B1 (en) 2002-04-19 2007-08-22 Smithkline Beecham Corporation Novel compounds
CA2494061C (en) 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003273675A1 (en) 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
DE602004021558D1 (en) * 2003-01-17 2009-07-30 Warner Lambert Co 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
ATE412650T1 (en) * 2003-07-11 2008-11-15 Warner Lambert Co ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
JP4616839B2 (en) 2003-11-13 2011-01-19 エフ．ホフマン−ラ ロシュ アーゲー Hydroxyalkyl-substituted pyrido-7-pyrimidin-7-ones
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
EP1786817A1 (en) * 2004-08-26 2007-05-23 Boehringer Ingelheim International GmbH Pteridinones used as plk (polo like kinases) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
UY29440A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd NEW COMPOUNDS
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd Novel compounds
PE20061193A1 (en) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38
CN101495475A (en) 2005-03-25 2009-07-29 葛兰素集团有限公司 Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
BRPI0617159B8 (en) * 2005-10-07 2021-05-25 Exelixis Inc pi3ka inhibitor pyridopyrimidinone compounds, compositions containing them, and preparation process
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2008032162A1 (en) 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
AU2007311480A1 (en) * 2006-10-16 2008-04-24 Forma Therapeutics, Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
AU2008237507B2 (en) * 2007-04-03 2014-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
HRP20161536T1 (en) 2007-06-15 2016-12-30 Msd K.K. Bicycloaniline derivative
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
BRPI0821209A2 (en) 2007-12-19 2019-09-24 Amgen Inc compound, pharmaceutical composition, methods of treating cancer, reducing tumor size, treating disorders, and reducing metastasis in a tumor.
US8466151B2 (en) 2007-12-26 2013-06-18 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
ATE531372T1 (en) 2008-04-07 2011-11-15 Amgen Inc GEM-DISUBSTITUTED AND SPIROCYCLIC AMINOPYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
WO2011044535A2 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
KR101754664B1 (en) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
AR080151A1 (en) 2010-02-09 2012-03-14 Exelixis Inc METHODS TO TREAT CANCER USING PI 3K PYRIDOPIRIMIDINONE INHIBITORS AND MTOR IN COMBINATION WITH AUTOPHAGIA INHIBITORS
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
BR112013002375B1 (en) 2010-08-05 2020-05-12 Temple University - Of The Commonwealth System Of Higher Education COMPOUND, SAME PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, AND, USES OF A COMPOUND
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
PT2646448T (en) 2010-11-29 2017-10-04 Osi Pharmaceuticals Llc Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
MX2013010871A (en) 2011-03-23 2014-01-31 Amgen Inc FUSIONED DOUBLE TRICICLIC INHIBITORS OF CDK 4/6 AND FLT3.
PL2710005T3 (en) * 2011-05-17 2017-07-31 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US9718821B2 (en) 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
TR201816077T4 (en) * 2013-02-21 2018-11-21 Pfizer Solid forms of a selective cdk4 / 6 inhibitor.
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
MY198534A (en) 2016-08-15 2023-09-04 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
CN110809576B (en) * 2017-03-03 2022-08-30 奥克兰联合服务有限公司 FGFR kinase inhibitor and pharmaceutical use
MX2020008559A (en) 2018-02-15 2021-01-08 Nuvation Bio Inc Heterocyclic compounds as kinase inhibitors.
TW202035406A (en) 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 Heterocyclic compounds as CDK-HDAC dual pathway inhibitors
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
KR102912922B1 (en) * 2021-03-08 2026-01-15 지난 유니버시티 Pyridopyrimidine compounds and their applications
EP4353724A4 (en) * 2021-06-09 2025-10-08 Tyk Medicines Zhengzhou Inc COMPOUND AS CDK KINASE INHIBITOR AND USE THEREOF
WO2024056091A1 (en) * 2022-09-16 2024-03-21 华东师范大学 Pyridonopyrimidine derivative as rsk inhibitor and use thereof
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
KR20000070751A (en) * 1997-02-05 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Pyrido[2,3-D]pyrimidines and 4-Aminopyrimidines as Inhibitors of Cellular Proliferation
KR20010043829A (en) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Bicyclic Pyrimidines and Bicyclic 3,4-Dihydropyrimidines as Inhibitors of Cellular Proliferation

Also Published As

Publication number Publication date
TNSN01036A1 (en) 2005-11-10
CO5280200A1 (en) 2003-05-30
KR20020075805A (en) 2002-10-05
ZA200207110B (en) 2003-12-04
AU2001233028A1 (en) 2001-10-03
DZ3308A1 (en) 2001-09-27
YU66502A (en) 2005-09-19
IS6524A (en) 2002-08-23
PE20011177A1 (en) 2001-11-23
CA2401368A1 (en) 2001-09-27
NO20024235D0 (en) 2002-09-05
PL358271A1 (en) 2004-08-09
SK12472002A3 (en) 2003-04-01
MXPA02008535A (en) 2002-12-13
NZ520962A (en) 2003-09-26
IL151480A0 (en) 2003-04-10
SV2001000338A (en) 2001-11-30
BR0109056A (en) 2003-06-03
CZ20022929A3 (en) 2003-02-12
AR034119A1 (en) 2004-02-04
PA8513201A1 (en) 2003-06-30
HUP0300136A2 (en) 2003-05-28
GT200100037A (en) 2002-03-04
NO20024235L (en) 2002-11-05
MA26881A1 (en) 2004-12-20
CR6736A (en) 2004-03-10
EA200200802A1 (en) 2003-02-27
AP2002002643A0 (en) 2002-12-31
WO2001070741A1 (en) 2001-09-27
JP2003528101A (en) 2003-09-24
OA12227A (en) 2004-03-18
HN2001000040A (en) 2001-09-06
CN1422268A (en) 2003-06-04
HRP20020798A2 (en) 2004-02-29
EP1268476A1 (en) 2003-01-02
EE200200506A (en) 2004-02-16

Similar Documents

Publication Publication Date Title
BG107161A (en) 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
GEP20063915B (en) PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
TR200102001T2 (en) Pyrazoles substituted as P38 kinase inhibitors
GEP20033093B (en) Bicyclic Pyrimidines and Bicyclic 3,4-Dihydropyrimidines as Inhibitors of Cellular Proliferation, Compositions Containing Them and Methods for Treating Cell Proliferative Disorders
YU50402A (en) Pyrido(2,3-d)pyrimidine-2,7-diamine kinase inhibitors
NO308108B1 (en) Pyrrolo [2,3-d] pyrimidines and their use in the manufacture of a drug
TNSN07281A1 (en) Pyrazole derivatives for the inhibition of cdk's and gsk's
BG104949A (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
UY27198A1 (en) NEW BENCIMIDAZOL ANTI-INFLAMMATORY COMPOUNDS
BG107960A (en) Ether derivatives useful as inhibitors of pde4 isozymes
MXPA02005844A (en) Inhibitors of protein kinases.
YU84603A (en) Novel tyrosine kinase inhibitors
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
NO20000702D0 (en) cGMP PDE inhibitors for the treatment of erectile dysfunction
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
NO2015020I1 (en) Ceritinib, 5-chloro-N-5-methyl-4- (piperidin-4-yl) -2 - [(propan-2-yl) oxy] phenyl-N- [2- (propan-2-sulfonyl) phenyl] pyrimidine-2,4-diamine, or a pharmaceutically acceptable salt thereof
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
MXPA02007981A (en) Substituted beta carbolines with ikb kinase inhibiting activity.
YU108791A (en) PYRAZOLOPYRIMIDINONE ANTIANGINAL COMPOUNDS
NZ333706A (en) Benzenesulfone derivatives and medicaments
MY110191A (en) 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
PT1758860E (en) Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in the treatment of pains, depressions and anxiety states
ATE353651T1 (en) 3-FURYLAN ALOGS OF TOXOFLAVIN AS KINASE INHIBITORS
MXPA05010975A (en) (6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis.